diminazene aceturate has been researched along with Parkinson Disease in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Gupta, S; Hanif, K; Mishra, A; Shukla, S; Tiwari, P; Tiwari, V | 1 |
| Adame, A; Clark, LN; Cote, L; Geddie, ML; Ju, S; Lewandowski, NM; Lindquist, S; Marder, K; Masliah, E; Muhammad, A; Petsko, GA; Ringe, D; Rockenstein, E; Ross, B; Small, SA; Verbitsky, M; Vonsattel, JP | 1 |
2 other study(ies) available for diminazene aceturate and Parkinson Disease
| Article | Year |
|---|---|
Angiotensin-Converting Enzyme 2 Activation Mitigates Behavioral Deficits and Neuroinflammatory Burden in 6-OHDA Induced Experimental Models of Parkinson's Disease.
Topics: Angiotensin I; Angiotensin-Converting Enzyme 2; Animals; Diminazene; Mice; Models, Theoretical; Oxidopamine; Parkinson Disease; Peptide Fragments; Peptidyl-Dipeptidase A; Proto-Oncogene Mas; Rats; Receptors, G-Protein-Coupled; Signal Transduction | 2022 |
Polyamine pathway contributes to the pathogenesis of Parkinson disease.
Topics: Acetyltransferases; alpha-Synuclein; Animals; Brain Stem; Diminazene; Genetic Variation; Humans; Magnetic Resonance Imaging; Mice; Mice, Transgenic; Parkinson Disease; Pemoline; Polyamines | 2010 |